Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
Pharmacy Choice | June 02, 2017
By a News Reporter-Staff News Editor at Health & Medicine Week Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Vifor Pharma Group. announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the United States upon approval by the U.S. Food and Drug Administration (FDA).